Beta-blockers May Boost Chemotherapy Response in Neuroblastoma
Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, according to a new study published today in the British Journal of Cancer.
Early Results Promising
Researchers from the Children’s Cancer Institute Australia (CCIA) found that three beta-blockers (carvedilol, nebivolol [Bystolic], and propranolol) were able to slow the growth of neuroblastoma cancer cells grown in the lab, and when combined with chemotherapy, these anticancer effects were increased. When the chemotherapy drug vincristine was added together with beta-blockers, survival was greatly improved in mice.
Study lead author Eddy Pasquier, PhD, Senior Research Officer in the Tumour Biology and Targeting Program at CCIA, said: “Three of the seven different beta-blockers tested in the lab all slowed tumor growth. When combined with these beta-blockers, vincristine was four times more effective than when used alone.”
Neuroblastoma is a cancer that develops from nerve cells left over from a baby’s development in the womb. Around 100 children are diagnosed with neuroblastoma each year in the United Kingdom, most of whom are under the age of 5. Despite the number of children surviving neuroblastoma rising from 17% in 1971 to 64% today, the aggressive form of the disease is still very hard to treat successfully.
More Work to Be Done
Julie Sharp, MD, Senior Science Information Manager at Cancer Research UK, said, "We urgently need more effective treatments for children with neuroblastoma, and this research opens up a new avenue to explore. But this approach has only been tested in mice, and may not have the same effect in children, so more work needs to be done to show whether this might work in the clinic."
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
